Literature DB >> 30208955

Some DNM2 mutations cause extremely severe congenital myopathy and phenocopy myotubular myopathy.

Valérie Biancalana1,2,3,4,5, Norma B Romero6,7,8, Inger Johanne Thuestad9, Jaakko Ignatius10, Janne Kataja11, Maria Gardberg12, Delphine Héron13, Edoardo Malfatti7,8, Anders Oldfors14, Jocelyn Laporte15,16,17,18.   

Abstract

Entities:  

Keywords:  Centronuclear myopathy; Congenital myopathy; DNM2; Hypotonia; MTM1

Mesh:

Substances:

Year:  2018        PMID: 30208955      PMCID: PMC6134552          DOI: 10.1186/s40478-018-0593-2

Source DB:  PubMed          Journal:  Acta Neuropathol Commun        ISSN: 2051-5960            Impact factor:   7.801


× No keyword cloud information.
Centronuclear myopathies (CNM) are rare congenital myopathies characterized by muscle weakness with facial and eye involvement and intracellular disorganisation of myofibers with centralized nuclei [5, 8]. Several forms and mode of inheritance have been described. The most severe form, also called X-linked myotubular myopathy, is due to MTM1 mutations and is associated with perinatal severe hypotonia and respiratory distress leading to death of most affected boys in infancy (MIM#310400) [7]. Dominant DNM2 mutations are linked to milder cases with either neonatal, childhood or adult onset and proximal or diffuse muscle weakness (MIM#160150) [2, 3]. Previously described neonatal DNM2 cases showed gradual improvement in motor function and survival into adulthood [1]. Unlike MTM1-CNM, reported cases of DNM2-CNM biopsies often show a radial distribution of sarcoplasmic strands on cross sections. Here we present three unrelated DNM2-CNM cases resembling myotubular myopathy at the clinical and histopathological levels. Two girls and one boy from unrelated families presented at birth with global and severe hypotonia with respiratory distress requiring invasive and permanent respiratory support (Additional file 1: Table S1). Patients 1 and 2 had multiple contractures. Patient 1 is a male born at 29 weeks of estimated gestational age (EGA), presenting with foetal akinesia and disturbance of cardiac rhythm. Hydramnios was detected. He had a congenital and bilateral chylothorax and died at 5 weeks from a bronchopulmonary dysplasia. Patient 2 is a girl delivered at term by cesarean section due to monotonic heart rate. No amniotic fluid was present. She presented with small intracerebral hemorrhages but no major brain malformations at 1.5 months, and developed 40 degrees convex scoliosis by 4 months. Extubation attempt at 5 months failed and she died at 8 months of age from pneumonia. Patient 3 is a girl born at 34 weeks of EGA. She had a bilateral ptosis and high-arched palate. Brain MRI uncovered a leukoencephalopathy with enlarged ventricles and reduced white matter. She died at 4 months from respiratory failure. Muscle biopsies were performed at 1 month from quadriceps for patients 1 and 3 and at autopsy at 8 months for patient 2. They showed fiber size variability and hypotrophic muscle fibers with prominent nuclear centralizations (Fig. 1a). No clusters of nuclei were observed (Additional file 1: Figure S1). NADH-TR staining revealed centrally located hyperintense reaction in the majority of fibers, without radial distribution of sarcoplasmic strands as the spokes of a wheel. Predominance of type 1 fiber was observed for patient 2 with more variability in fiber size and some increase in connective tissue. Electron microscopy ultrastructural analysis in patient 1 confirmed the presence of prominent nuclear centralizations. Of note centralized nuclei were surrounded by amorphous material and partially disorganized and misaligned sarcomeres. Satellite cells count appeared normal unlike neonates with myotubular myopathy in whom a decrease was noted [9](Fig. 1b).
Fig. 1

a. Hematoxilin-eosin (HE) and nicotinamide adenosine dinucleotide-tetrazolium reductase (NADH-TR) staining of muscles from the patients, showing fibers with centralized nuclei (HE) and abnormal central accumulation oxidative staining and a paler peripheral halo. Scale bars 20 μm. b. Electron microscopy of patient 1 muscle showing partial sarcomeres disorganisation and central nuclei. Scale bar 10 μm. c. Localization of presently reported mutations (dark blue) compared to known DNM2-CNM mutations (red) on the 3D model of nucleotide-free human DNM1 (PDB 3SNH). They all clusterize at the PH (yellow) – Middle/stalk (light blue) interface (green line)

a. Hematoxilin-eosin (HE) and nicotinamide adenosine dinucleotide-tetrazolium reductase (NADH-TR) staining of muscles from the patients, showing fibers with centralized nuclei (HE) and abnormal central accumulation oxidative staining and a paler peripheral halo. Scale bars 20 μm. b. Electron microscopy of patient 1 muscle showing partial sarcomeres disorganisation and central nuclei. Scale bar 10 μm. c. Localization of presently reported mutations (dark blue) compared to known DNM2-CNM mutations (red) on the 3D model of nucleotide-free human DNM1 (PDB 3SNH). They all clusterize at the PH (yellow) – Middle/stalk (light blue) interface (green line) MTM1 mutations were excluded in patients 1 and 3. All the patients were found with heterozygous de novo DNM2 mutations, NM_001005360.2: c.1831G > A - p.Glu611Lys, c.1090C > T - p.Arg364Cys, and c.1856C > T - p.Ser619Leu for patient 1, 2 and 3 respectively, through direct Sanger sequencing or an arthrogryposis gene panel (CeGaT, Tübingen, Germany). The p.Ser619Leu mutation was reported in at least 11 CNM cases with neonatal onset and a milder course compared to the present cohort. Mutations p.Glu611Lys and p.Arg364Cys are novel and are not found in gnomAD (http://gnomad.broadinstitute.org/). They affect aminoacids conserved down to drosophila and are predicted pathogenic by SIFT and Polyphen-2. Furthermore, they cluster with most known mutations on the 3D structure (Fig. 1c). Here we report the most severe CNM patients with heterozygous DNM2 mutations. Compared to previously reported DNM2-CNM cases [3], they were fully dependent on invasive ventilation and all died within the first months of life. The very early lethal outcome in patient 1 may have been influenced by concomitant prematurity. Nevertheless, the three patients did not improve except for a slight muscle strength enhancement appearing after 6 months of age in patient 2. Furthermore, early developmental milestones were delayed (Additional file 1: Table S1), in contrast with some previously described neonatal onset DNM2 patients [4]. This study enlarges the clinical and genetic spectrum of DNM2-CNM. Moreover, it underlines that DNM2 mutations can be associated with decreased survival. In addition to a CNM phenotype, the 3 patients display similar features with the lethal congenital contracture syndrome (MIM#615368) due to a DNM2 homozygous mutation [6], especially multiple contractures, fetal hypokinesia, pulmonary hypertension, brain hemorrhages, and abnormal fetal heart rythm. The present DNM2-CNM cases were highly similar to myotubular myopathy due to MTM1 mutations, although none of them presented with the association of facial hypotonia, ptosis, ophthalmoplegia and elongated face that is typical in MTM1-CNM cases. In addition to the perinatal severity, they had very severe hypotonia, respiratory distress and the same histopathological findings, lacking the radial strands hallmark of most other DNM2 cases. In conclusion, DNM2 should be investigated in congenital myopathies presenting as myotubular myopathy. Clinical, molecular, histopathological and ultrastructural findings for the patients. Table S1 Clinical and molecular findings in the DNM2 severe cases. Figure S1 Histopathological and ultrastructural findings for the patients. Patients 1, 2 and 3: Hematoxilin-eosin (HE) staining of muscles showing fibers with centralized nuclei. Patient 1: ATPase at pH 9.4 showing type I (pale) and type II (dark) fibers. Patient 3: ATPase at pH 4.6 showing type 1 fibers dark and type 2 fibers less stained. Scale bars 20 μm. (ZIP 46909 kb)
  9 in total

1.  Mutation spectrum in the large GTPase dynamin 2, and genotype-phenotype correlation in autosomal dominant centronuclear myopathy.

Authors:  Johann Böhm; Valérie Biancalana; Elizabeth T Dechene; Marc Bitoun; Christopher R Pierson; Elise Schaefer; Hatice Karasoy; Melissa A Dempsey; Fabrice Klein; Nicolas Dondaine; Christine Kretz; Nicolas Haumesser; Claire Poirson; Anne Toussaint; Rebecca S Greenleaf; Melissa A Barger; Lane J Mahoney; Peter B Kang; Edmar Zanoteli; John Vissing; Nanna Witting; Andoni Echaniz-Laguna; Carina Wallgren-Pettersson; James Dowling; Luciano Merlini; Anders Oldfors; Lilian Bomme Ousager; Judith Melki; Amanda Krause; Christina Jern; Acary S B Oliveira; Florence Petit; Aurélia Jacquette; Annabelle Chaussenot; David Mowat; Bruno Leheup; Michele Cristofano; Juan José Poza Aldea; Fabrice Michel; Alain Furby; Jose E Barcena Llona; Rudy Van Coster; Enrico Bertini; Jon Andoni Urtizberea; Valérie Drouin-Garraud; Christophe Béroud; Bernard Prudhon; Melanie Bedford; Katherine Mathews; Lori A H Erby; Stephen A Smith; Jennifer Roggenbuck; Carol A Crowe; Allison Brennan Spitale; Sheila C Johal; Anthony A Amato; Laurie A Demmer; Jessica Jonas; Basil T Darras; Thomas D Bird; Mercy Laurino; Selman I Welt; Cynthia Trotter; Pascale Guicheney; Soma Das; Jean-Louis Mandel; Alan H Beggs; Jocelyn Laporte
Journal:  Hum Mutat       Date:  2012-04-04       Impact factor: 4.878

Review 2.  Centronuclear myopathies: a widening concept.

Authors:  Norma Beatriz Romero
Journal:  Neuromuscul Disord       Date:  2010-02-23       Impact factor: 4.296

3.  Mutations in dynamin 2 cause dominant centronuclear myopathy.

Authors:  Marc Bitoun; Svetlana Maugenre; Pierre-Yves Jeannet; Emmanuelle Lacène; Xavier Ferrer; Pascal Laforêt; Jean-Jacques Martin; Jocelyn Laporte; Hanns Lochmüller; Alan H Beggs; Michel Fardeau; Bruno Eymard; Norma B Romero; Pascale Guicheney
Journal:  Nat Genet       Date:  2005-10-16       Impact factor: 38.330

4.  Dynamin 2 homozygous mutation in humans with a lethal congenital syndrome.

Authors:  Olga S Koutsopoulos; Christine Kretz; Claudia M Weller; Aurelien Roux; Halina Mojzisova; Johann Böhm; Catherine Koch; Anne Toussaint; Emilie Heckel; Daphne Stemkens; Simone A J Ter Horst; Christelle Thibault; Muriel Koch; Syed Q Mehdi; Emilia K Bijlsma; Jean-Louis Mandel; Julien Vermot; Jocelyn Laporte
Journal:  Eur J Hum Genet       Date:  2012-10-24       Impact factor: 4.246

5.  A gene mutated in X-linked myotubular myopathy defines a new putative tyrosine phosphatase family conserved in yeast.

Authors:  J Laporte; L J Hu; C Kretz; J L Mandel; P Kioschis; J F Coy; S M Klauck; A Poustka; N Dahl
Journal:  Nat Genet       Date:  1996-06       Impact factor: 38.330

6.  Dynamin 2 mutations cause sporadic centronuclear myopathy with neonatal onset.

Authors:  Marc Bitoun; Jorge A Bevilacqua; Bernard Prudhon; Svetlana Maugenre; Ana Lia Taratuto; Soledad Monges; Fabiana Lubieniecki; Claude Cances; Emmanuelle Uro-Coste; Michèle Mayer; Michel Fardeau; Norma B Romero; Pascale Guicheney
Journal:  Ann Neurol       Date:  2007-12       Impact factor: 10.422

Review 7.  Centronuclear (myotubular) myopathy.

Authors:  Heinz Jungbluth; Carina Wallgren-Pettersson; Jocelyn Laporte
Journal:  Orphanet J Rare Dis       Date:  2008-09-25       Impact factor: 4.123

8.  Extensive morphological and immunohistochemical characterization in myotubular myopathy.

Authors:  Minobu Shichiji; Valérie Biancalana; Michel Fardeau; Jean-Yves Hogrel; Makiko Osawa; Jocelyn Laporte; Norma Beatriz Romero
Journal:  Brain Behav       Date:  2013-06-19       Impact factor: 2.708

9.  Centronuclear myopathy related to dynamin 2 mutations: clinical, morphological, muscle imaging and genetic features of an Italian cohort.

Authors:  Michela Catteruccia; Fabiana Fattori; Valentina Codemo; Lucia Ruggiero; Lorenzo Maggi; Giorgio Tasca; Chiara Fiorillo; Marika Pane; Angela Berardinelli; Margherita Verardo; Cinzia Bragato; Marina Mora; Lucia Morandi; Claudio Bruno; Lucio Santoro; Elena Pegoraro; Eugenio Mercuri; Enrico Bertini; Adele D'Amico
Journal:  Neuromuscul Disord       Date:  2013-02-08       Impact factor: 4.296

  9 in total
  3 in total

Review 1.  Centronuclear Myopathy Caused by Defective Membrane Remodelling of Dynamin 2 and BIN1 Variants.

Authors:  Kenshiro Fujise; Satoru Noguchi; Tetsuya Takeda
Journal:  Int J Mol Sci       Date:  2022-06-03       Impact factor: 6.208

2.  Panorama of the distal myopathies.

Authors:  Marco Savarese; Jaakko Sarparanta; Anna Vihola; Per Harald Jonson; Mridul Johari; Salla Rusanen; Peter Hackman; Bjarne Udd
Journal:  Acta Myol       Date:  2020-12-01

3.  Benefits of therapy by dynamin-2-mutant-specific silencing are maintained with time in a mouse model of dominant centronuclear myopathy.

Authors:  Delphine Trochet; Bernard Prudhon; Lylia Mekzine; Mégane Lemaitre; Maud Beuvin; Laura Julien; Sofia Benkhelifa-Ziyyat; Mai Thao Bui; Norma Romero; Marc Bitoun
Journal:  Mol Ther Nucleic Acids       Date:  2022-02-13       Impact factor: 8.886

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.